Cure My Disease

Don't miss your cure!

 Log in / Sign up

Withdrawn study sought to test amino Acid's effect on insulin sensitivity

NCT ID NCT07329088

Knowledge-focused Sponsor: Jean L. Fry Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to see if adding the amino acid isoleucine to a healthy, low-isoleucine diet would change how the body responds to insulin in people with obesity and prediabetes. It planned to enroll adults with a BMI of 30 or higher who also had metabolic syndrome. The study was withdrawn before any participants were enrolled, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * BMI ≥ 30 * Meeting at least three metabolic syndrome criteria * Follow an American style diet Exclusion Criteria: * Type 1 or 2 Diabetes diagnosis * Medical condition or medication that affects insulin sensitivity, weight, or metabolism * More than 5% weight change in 3 previous months * Restrictive dietary pattern * History of bariatric surgery * Food allergy more severe than grade 1 on the CoFAR Grading Scale for Systemic Allergic Reactions, Version 3.0 * Allergy to lidocaine.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic syndrome (METS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome glucose intolerance hyperglycemia Insulin Resistance metabolic syndrome X Obesity obesity disorder Overweight prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic syndrome (METS) Obesity & overweight Prediabetes (insulin resistance, impaired glucose tolerance)

Contacts and locations

Locations

  • University of Kentucky

    Lexington, Kentucky, 40536, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.